MabCure Inc. Welcomes Dr. David S. Frank As New Member of the Board of Directors
27 Abril 2009 - 1:46PM
Business Wire
MabCure, Inc. (�MabCure�), a biotechnology company using its
proprietary technology to create highly specific monoclonal
antibodies (MAbs) for the early detection of cancer, welcomes Dr.
David S. Frank to the company�s board of directors.
Dr. Frank has held a number of senior level executive positions
at major public companies. Most recently he assumed the position of
Managing Director at the privately held MEDx Associates LLC, a
diagnostics and medical devices consulting company. Prior to that
Dr. Frank served as Executive Director of Business Development at
Ortho Clinical Diagnostics, a Johnson & Johnson company.
Dr. Frank�s industrial career began as a founding member of
Kodak�s thin film diagnostics research and development team, where,
over a nine-year period he was granted ten patents. As Director of
Marketing and Planning Management at Kodak Clinical Diagnostics
from 1982-1994, Dr. Frank served as head of point of care
diagnostics; regional business manager for Asia, Africa, and
Australia; and Director of Diagnostics Marketing for Japan. Dr.
Frank, who earned his biochemistry PhD from Cornell University,
recently served as a faculty member at the LAHAV-Tel Aviv
University Graduate School of Business, where he taught at health
care marketing courses for bioscience entrepreneurs.
Dr. Frank is currently the Chairman of the Board of Nehora
Photonics Ltd., a medical device company located in Israel, and a
board member of TogetherForever LLC.
�We are delighted to welcome David to the board,� said Dr. Amnon
Gonenne, MabCure�s President and CEO. �David�s breadth of
international business development and marketing experience is
certain to be instrumental to the future of MabCure. With David�s
leadership and expertise, we anticipate the company will accelerate
toward the achievement of the shared goals of our shareholders,
employees, customers, and patients alike.�
For more news and information on�MabCure Inc., please visit
www.IRGnews.com/coi/MBCI where you can find a fact sheet on the
company, investor presentations, and more.
About MabCure Inc.
MabCure is a biotechnology company whose vision is to change the
perception of cancer as being a largely incurable disease. MabCure
owns proprietary technology for the creation of unique and highly
specific monoclonal antibodies (MAbs), which will be developed as
diagnostic tools, imaging agents, and drugs to treat lethal
cancers. MabCure initial goal is to develop its novel MAbs as
diagnostic tools for the detection of Ovarian and Prostate cancers
at an early stage, when these diseases are still localized and
highly curable. For further information visit the Company�s website
www.mabcure.com.
This news release contains �forward-looking statements�.
Statements in this news release which are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the change of business focus of the
management of the Company or the University and the inability of
the Company or the University to pursue its current objectives.
These forward-looking statements are made as of the date of this
news release and the Company or the University assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements.
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
